Boyd said the hope is that operability will move toward regional interoperability -- meaning all regional systems with different protocols and technologies will communicate on a national scale.

Background: The neoadjuvant (NA) treatment for non-small cell lung cancer (NSCLC) has evolved with the emergence of chemotherapy (CT) and immunotherapy (IO) combinations as the standard of care.